Erasca 過去の業績

過去基準チェック /06

Erascaの収益は年平均-18%で減少しているが、Biotechs業界はgrowingで19.3%年平均の収益となった。

主要情報

-18.0%

収益成長率

30.3%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	-35.4%
ネット・マージン	n/a
前回の決算情報	30 Sep 2024

Recent updates

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28

収支内訳

Erasca の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:ERAS 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Sep 24	-159	40	111
30 Jun 24	-158	39	109
31 Mar 24	-127	39	105
31 Dec 23	-125	38	104
30 Sep 23	-231	38	110
30 Jun 23	-236	37	113
31 Mar 23	-240	36	114
31 Dec 22	-243	34	114
30 Sep 22	-138	31	107
30 Jun 22	-149	29	99
31 Mar 22	-141	26	89
31 Dec 21	-123	23	74
30 Sep 21	-154	19	60
30 Jun 21	-119	14	49
31 Mar 21	-96	10	37
31 Dec 20	-102	8	30

質の高い収益: ERASは現在利益が出ていません。

利益率の向上: ERASは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ERASは利益が出ておらず、過去 5 年間で損失は年間18%の割合で増加しています。

成長の加速: ERASの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ERASは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: ERASは現在利益が出ていないため、自己資本利益率 ( -35.36% ) はマイナスです。

Erasca 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca: New Focus After Restructuring, But Need More Differentiation

Erasca, Inc. Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

Independent Director recently bought US$182k worth of stock

Price target decreased by 11% to US$6.25

New major risk - Shareholder dilution

Erasca, Inc. has completed a Follow-on Equity Offering in the amount of $159.999999 million.

New minor risk - Shareholder dilution

Erasca, Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Erasca, Inc. announced that it expects to receive $45 million in funding

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Co-Founder recently bought US$1.7m worth of stock

Price target decreased by 7.4% to US$9.00

Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$2.0m worth of stock

New minor risk - Share price stability

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Co-Founder recently bought US$275k worth of stock

New minor risk - Share price stability

Price target decreased by 19% to US$11.50

Erasca, Inc. Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca, Inc. Announces Promising Preliminary Data for ERAS-007 Combinations in Patients with Gastrointestinal Malignancies as Part of Two Poster Presentations That Will Be Presented At the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

Erasca, Inc. Further Strengthens Business Leadership with Two Key Promotions

Independent Director recently bought US$55k worth of stock

Price target decreased by 9.3% to US$15.57

Co-Founder recently bought US$284k worth of stock

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Co-Founder recently bought US$231k worth of stock

Co-Founder recently bought US$200k worth of stock

Price target decreased to US$18.60

Erasca, Inc. Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces Preliminary Data for Eras-007 and Eras-601 in Braf-Driven and Ras/Mapk-Altered Solid Tumors

Erasca adds 10% ahead of R&D Day

Erasca, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Erasca, Inc.(NasdaqGS:ERAS) dropped from Russell 2000 Growth Index

Erasca, Inc. Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

Erasca, Inc. Announces Key Appointments

Erasca Appoints Jean Liu to its Board of Directors

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces FDA Clearance of IND Application for Eras-801 in Glioblastoma Multiforme

Erasca, Inc. Announces First Patient Dosed in HERKULES-3, A Phase 1B/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca, Inc. has completed an IPO in the amount of $300 million.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06